1. What Is the Liquid Biopsy Circulating Tumor DNA Market?
The Liquid Biopsy Circulating Tumor DNA Market comprises blood-based assays that detect and analyze cell-free tumor DNA fragments shed by cancer cells into peripheral blood for oncology applications. The market includes plasma ctDNA extraction systems, targeted sequencing panels, digital PCR platforms, and bioinformatics pipelines for somatic mutation and copy number alteration analysis. These assays serve oncologists, clinical reference laboratories, and academic centers for treatment selection, minimal residual disease monitoring, and therapy resistance assessment. The scope excludes germline hereditary cancer gene testing, methylation-based multi-cancer screening assays, and tissue biopsy sequencing that does not involve blood-based cell-free DNA isolation.
2. Liquid Biopsy Circulating Tumor DNA Market Size & Forecast
3. Emerging Technologies
- Error-corrected sequencing chemistry using molecular barcodes is advancing to reduce background sequencing error and improve ctDNA detection sensitivity at sub-0.1 percent allele fractions. Growing adoption of barcode-based error correction is improving detection of rare ctDNA variants in early-stage cancer and post-treatment minimal residual disease scenarios.
- Tumor-informed personalized ctDNA panel design is advancing using whole-exome sequencing of matched tumor tissue to identify a custom variant set tracked in blood. Increasing clinical deployment of tumor-informed assays is improving sensitivity for detecting residual cancer compared with tumor-agnostic fixed panel approaches.
- Multi-analyte liquid biopsy platforms combining ctDNA with protein biomarkers and fragmentomics are advancing to improve early cancer detection specificity at low tumor fractions. Continued development of multi-marker blood tests is improving cancer signal detection and reducing false positives in cancer screening applications.
- Cell-free DNA fragmentome analysis examining nucleosome positioning and fragment length patterns is advancing to infer tissue of origin and cancer type without variant-specific sequencing. Expanding fragmentomics applications are enabling cancer tissue-of-origin classification from plasma cell-free DNA without prior tumor genomic profiling.
Such innovations are driving change across adjacent industries too. Discover more in our Liquid Biopsy Exosome Market.
4. Key Market Opportunity
A major opportunity in the Liquid Biopsy Circulating Tumor DNA Market is the integration of serial ctDNA monitoring into routine oncology follow-up care as a real-time molecular response tool. Many cancer patients completing curative treatment lack a validated blood-based method to detect molecular residual disease before clinical or radiological progression becomes evident. Advances in error-corrected sequencing, tumor-informed panel design, and clinical validation frameworks are improving ctDNA monitoring sensitivity and enabling residual disease detection at clinically actionable timelines. Diagnostic companies qualifying validated ctDNA monitoring assays for post-treatment surveillance stand to generate sustained revenue from oncology follow-up testing across multiple tumor types.
5. Top Companies in the Liquid Biopsy Circulating Tumor DNA Market
The following organisations hold leading positions in the Liquid Biopsy Circulating Tumor DNA Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Guardant Health
- Foundation Medicine (Roche)
- Natera (Signatera)
- Exact Sciences
- Personal Genome Diagnostics
- Illumina
- Bio-Techne
- Sysmex Inostics
- Caris Life Sciences
- Inivata
- Resolution Bioscience
- PrediLife
6. Market Segmentation
The Liquid Biopsy Circulating Tumor DNA Market is analysed across 7 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Assay Type | Comprehensive Genomic Profiling Somatic Mutation Panel Minimal Residual Disease Monitoring Treatment Response Assessment Tumor Mutational Burden Analysis |
| By Technology | High-Throughput Sequencing Targeted Panel Sequencing Whole Exome Sequencing Digital PCR Droplet Digital PCR Shallow Whole Genome Sequencing |
| By Cancer Type | Non-Small Cell Lung Cancer Breast Cancer Colorectal Cancer Prostate Cancer Hematological Cancers |
| By Clinical Application | Companion Diagnostics FDA-Cleared CDx Therapy Monitoring Recurrence Detection Biomarker Identification |
| By Sample Type | Plasma ctDNA Cell-Free Plasma Cerebrospinal Fluid ctDNA Urine ctDNA |
| By End User | Academic Medical Centers Comprehensive Cancer Centers Clinical Reference Laboratories Community Oncology Practices Pharmaceutical Research Organizations |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Liquid Biopsy Circulating Tumor DNA Market trajectory over the forecast period:
Companion Diagnostic Approvals Are Expanding ctDNA Clinical Utility Across Tumor Types.Regulatory agencies are clearing ctDNA assays as companion diagnostics for targeted therapies, expanding clinical deployment from research to routine oncology prescribing for molecularly characterized patients. Foundation Medicine advanced its FoundationOne Liquid CDx comprehensive genomic profiling panel in 2024, expanding companion diagnostic coverage for additional targeted therapy approvals.
Minimal Residual Disease Detection by ctDNA Is Advancing as a Therapy Response Monitoring Approach.Oncologists are incorporating serial ctDNA monitoring after curative-intent treatment to detect molecular residual disease before conventional imaging identifies clinical or radiological progression. Natera progressed its Signatera personalized ctDNA monitoring assay clinical program in 2024, expanding tumor-informed MRD detection coverage across multiple solid tumor indications.
FDA-Cleared Blood-Based Cancer Screening Tests Are Establishing ctDNA Clinical Precedent.Colorectal cancer ctDNA screening tests approved by regulators are demonstrating the clinical validity of blood-based cancer detection and creating reimbursement pathways for future ctDNA applications. Guardant Health received FDA approval for its Guardant Shield colorectal cancer screening blood test in July 2024, validating ctDNA as a primary screening modality for averting invasive colonoscopy.
For related market intelligence, see the Liquid Biopsy Circulating Tumor Cell Market.
8. Segmental Analysis
By Clinical Application, the companion diagnostics segment dominated the Liquid Biopsy Circulating Tumor DNA Market in 2025, driven by FDA-cleared ctDNA CDx tests required for targeted therapy prescribing decisions. Oncologists continue directing ctDNA testing primarily toward companion diagnostic applications owing to regulatory-mandated requirements and payer coverage linked to approved therapy selection. Minimal residual disease monitoring is the fastest-growing Clinical Application category, driven by oncologist interest in detecting molecular residual disease after curative-intent surgery or chemotherapy. Clinical programs are advancing ctDNA MRD surveillance as evidence accumulates for early recurrence detection improving outcome compared with conventional imaging-based follow-up.
By Cancer Type, non-small cell lung cancer dominated the Liquid Biopsy Circulating Tumor DNA Market in 2025, driven by multiple FDA-approved ctDNA companion diagnostics for targeted EGFR, ALK, and KRAS therapies. Oncologists continue ordering ctDNA-based companion diagnostics for lung cancer owing to high targeted therapy eligibility rates and the clinical precedent of liquid biopsy in lung cancer prescribing. Colorectal cancer is the fastest-growing Cancer Type category, driven by ctDNA cancer screening approvals and growing MRD application in adjuvant therapy decision-making. Oncologists are advancing ctDNA use in colorectal cancer as Guardant Shield approval expands screening and MRD evidence supports adjuvant chemotherapy guidance decisions.
9. Regional Analysis
Regional demand patterns across the Liquid Biopsy Circulating Tumor DNA Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Liquid Biopsy Circulating Tumor DNA Market in 2025, holding 48.2% of the global market. Concentrated oncology drug development activity, multiple FDA-cleared ctDNA companion diagnostics, and large academic cancer center research programs across the United States anchor North American ctDNA assay revenue. FDA companion diagnostic approval pathways and CMS coverage decisions for targeted therapy ctDNA testing are sustaining high commercial deployment rates across US oncology practices. US pharmaceutical clinical trial programs requiring ctDNA companion diagnostics and pharmacodynamic monitoring are generating large-volume laboratory service demand for ctDNA platforms.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 27.40% during the forecast period. Expanding oncology clinical trial infrastructure, rising cancer incidence, and growing molecular oncology program development across China, Japan, India, and South Korea are driving ctDNA adoption. National cancer center programs and genomic medicine initiatives are incorporating ctDNA panels into precision oncology care pathways for lung, breast, and colorectal cancer management. Improving sequencing infrastructure and falling sequencing costs are expanding ctDNA test access beyond major academic centers to regional clinical laboratories.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Liquid Biopsy Circulating Tumor DNA Market was valued at USD 2.41 Bn in 2025 and is projected to reach USD 14.88 Bn by 2034, growing at a CAGR of 22.40% over the 2026–2034 forecast period.
The Liquid Biopsy Circulating Tumor DNA Market is projected to grow at a CAGR of 22.40% from 2026 to 2034.
North America accounted for the largest share of the Liquid Biopsy Circulating Tumor DNA Market in 2025, holding 48.2% of the global market.
The leading companies in the Liquid Biopsy Circulating Tumor DNA Market include Guardant Health, Foundation Medicine (Roche), Natera (Signatera), Exact Sciences, Personal Genome Diagnostics, Illumina, Bio-Techne, Sysmex Inostics, Caris Life Sciences, Inivata, Resolution Bioscience, PrediLife.
Companion diagnostic approvals are expanding ctdna clinical utility across tumor types.
By Clinical Application, the companion diagnostics segment dominated the Liquid Biopsy Circulating Tumor DNA Market in 2025, driven by FDA-cleared ctDNA CDx tests required for targeted therapy prescribing decisions.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.